Meyahealth
HomeGeneticsConditionGordon Holmes syndrome
Back to Condition
Gordon Holmes syndrome
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Gordon Holmes syndrome

Gordon Holmes syndrome is a rare genetic condition characterized by reproductive and neurological problems. Affected individuals often experience delayed puberty alongside progressive difficulties with speech and coordination.

Overview

Gordon Holmes syndrome is a rare condition characterized by reproductive and neurological problems. One of the key features of the condition is reduced production of hormones that direct sexual development, a condition known as hypogonadotropic hypogonadism.

Symptoms & Clinical Features

The signs and symptoms of Gordon Holmes syndrome typically unfold in stages, affecting both reproductive development and neurological function:

Reproductive Symptoms

  • Delayed development of the typical signs of puberty, such as the growth of facial hair and deepening of the voice in males, and the start of monthly periods (menstruation) and breast development in females.
  • Some affected individuals never undergo puberty.
  • Some individuals may experience normal puberty but develop other reproductive system problems later in life.

Neurological Symptoms

In early adulthood, individuals develop neurological problems, which typically include:

  • Speech difficulties (dysarthria)
  • Progressive problems with balance and coordination (cerebellar ataxia), often leading to difficulties with activities of daily living and requiring wheelchair assistance.
  • Memory problems and a decline in intellectual function (dementia) in some affected individuals.

Frequency

Gordon Holmes syndrome is a rare condition. Its prevalence is unknown.

Causes & Genetic Factors

Gordon Holmes syndrome can be caused by mutations in the RNF216 or PNPLA6 gene. Some individuals do not have mutations in these genes, indicating that other unidentified genes may also be involved.

  • RNF216 Gene: This gene produces a protein involved in ubiquitination, a cellular process that tags unneeded proteins with a molecule called ubiquitin so they can be broken down. One of the proteins tagged by RNF216 is found in nerve cells (neurons) and plays a role in synaptic plasticity—the ability of connections between neurons to adapt over time, which is critical for learning and memory. Mutations in RNF216 impair this tagging process, disrupting normal synaptic connections and likely contributing to dementia.
  • PNPLA6 Gene: This gene provides instructions for making a protein called neuropathy target esterase (NTE). NTE helps regulate the levels of certain fats (lipids) in the cell membrane, which is critical for membrane stability and function, particularly in the nervous system. NTE is also thought to help the pituitary gland release hormones that direct sexual development and growth. Mutations in PNPLA6 are thought to impair NTE function, altering lipid balance, damaging neurons in the brain (causing cerebellar ataxia), and preventing the pituitary gland from releasing key hormones (leading to hypogonadotropic hypogonadism). Individuals with Gordon Holmes syndrome caused by PNPLA6 mutations do not appear to develop dementia.

Associated Genes

  • PNPLA6
  • RNF216

Inheritance Pattern

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • Cerebellar ataxia and hypogonadotropic hypogonadism
  • Deficiency of luteinizing hormone-releasing hormone with ataxia

Frequently Asked Questions

Diagnosis of Gordon Holmes syndrome typically involves a combination of clinical evaluation, hormone testing, and neurological assessments. Delayed puberty and hypogonadotropic hypogonadism are key reproductive indicators, while neurological problems like speech difficulties (dysarthria) and progressive balance issues (cerebellar ataxia) usually emerge in early adulthood. Genetic testing for mutations in genes like RNF216 or PNPLA6 can confirm the diagnosis, though some cases may involve other unidentified genes.
Treatment for Gordon Holmes syndrome is primarily supportive and aims to manage symptoms. Reproductive issues like delayed puberty can be addressed with hormone replacement therapy to induce puberty and maintain hormone levels. For neurological symptoms, physical therapy, occupational therapy, and speech therapy can help manage balance problems, coordination difficulties, and speech impairments. Medications may be used to manage specific neurological symptoms, though there is no cure for the progressive neurological decline.
Gordon Holmes syndrome is a rare genetic condition, and its inheritance pattern can vary depending on the specific gene mutation involved. It is often inherited in an autosomal recessive manner, meaning both parents must carry a copy of the mutated gene for a child to be affected. Genetic counseling is highly recommended for affected individuals and their families to understand the specific inheritance pattern, assess recurrence risks, and discuss options for genetic testing for at-risk family members.
Neurological symptoms in Gordon Holmes syndrome typically begin in early adulthood and are progressive. Individuals often first experience speech difficulties (dysarthria) and problems with balance and coordination (cerebellar ataxia), which can worsen over time, eventually requiring wheelchair assistance for mobility. Some individuals may also develop memory problems and a decline in intellectual function (dementia). Supportive care includes regular physical therapy to maintain mobility and strength, occupational therapy to adapt to daily living challenges, and speech therapy to improve communication.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ